The continuous selective hydrogenation of the iodo-nitroaromatic refametinib active pharmaceutical ingredient (API) intermediate (2,3-difluoro-5-methoxy-6-nitro-phenyl)-(2-fluoro-4-iodo-phenyl)-amine (DIM-NA) to the corresponding iodo-aniline 3,4-difluoro-N2-(2-fluoro-4-iodo-phenyl)-6-methoxy-benzene-1,2-diamine (DIM-DAB) was investigated using a conventional Raney cobalt catalyst in a cocurrent trickle-bed reactor. Suitable reaction conditions targeting full conversion and high selectivity, that is, low degrees of hydro-dehalogenation of the labile iodine substituent, were evaluated in investigations employing a short 4 mL screening reactor. The process was then transferred to a longer 40 mL reactor. Raney cobalt was found to be a highly selective catalyst, yielding only very small amounts of the desiodinated aniline desiodo-DIM-DAB or other side products. Productivities up to 144 g/h crude DIM-DAB were achieved operating the 40 mL reactor with a 0.2 M reactant solution in the presence of 3.4 equiv of H2 at 60 °C. Inlet pressure resulting from the flow rate increase was identified as a key parameter for successful throughput maximization. One kilogram of starting material was eventually converted to DIM-DAB in high yield and excellent quality within 8 h runtime. Online monitoring of the UV–vis absorption of the product stream allowed for conversion control and fast detection of process variations. Compared to the available DIM-NA batch reduction procedures, processing in continuous flow proves convincing by the safe implementation and reusability of the Raney type catalyst within a strongly intensified and highly selective process.

• Bayer AG
• Leibniz-Institut für Katalyse e.V. (LIKAT)

• Intermediate
• API

1. API
2. DIM-DAB
3. DIM-NA
4. HPLC
5. hydrogenation
6. Intermediate
7. Raney Cobalt Catalyst
8. Refametinib Iodo-nitroaniline
9. Research Article